Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

Sumitomo designs new NHE inhibitors

Aug. 24, 2001

Natrecor launch quickly follows first approval in U.S.

Aug. 23, 2001

Phase II study of CETi-1 cholesterol vaccine from Avant initiated

Aug. 23, 2001

Aventis develops a new series of Na+/H+ exchange inhibitors

Aug. 22, 2001

ETA receptor antagonist attenuates angiotensin II- and noradrenaline-induced vasoconstriction

Aug. 22, 2001

New applications for irbesartan submitted in Europe and the U.S.

Aug. 21, 2001

New antiarrhythmic agents identified at BMS

Aug. 14, 2001

FDA approves Natrecor for treatment of congestive heart failure

Aug. 14, 2001

Approval of Remodulin recommended by the FDA for pulmonary arterial hypertension

Aug. 14, 2001

Enrollment completed in novel trial for prevention of hypertension

Aug. 14, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...